R&D News | pharmaphorum

News

AstraZeneca buys cell therapy biotech for up to $1bn

AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.

News

Vertanical's chief executive, Dr Clemens Fischer

Vertanical's cannabis-based painkiller hits target in trials

A cannabis-derived drug developed by Vertanical has shown efficacy in phase 3 for chronic back pain and could reach its first markets soon.

News

Latigo raises $150m for non-opioid painkiller push

Latigo has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million in a Series B.

News

Taiho snaps up ADC partner Araris for up to $1.14bn

Taiho has reached a deal to buy Swiss biotech Araris, around 18 months after they started collaborating on antibody-drug conjugates for cancer.

News

AbbVie builds the case for ovarian cancer drug Elahere

AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data.

News

Sutro puts lead ADC on hold, cuts staff and changes CEO

Sutro has shelved its lead drug for ovarian cancer and turned its attention to three preclinical candidates in a major shake-up of its business.

AstraZeneca buys cell therapy biotech for up to $1bn

Vertanical's cannabis-based painkiller hits target in trials

Latigo raises $150m for non-opioid painkiller push

Taiho snaps up ADC partner Araris for up to $1.14bn

AbbVie builds the case for ovarian cancer drug Elahere

Sutro puts lead ADC on hold, cuts staff and changes CEO

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks